Clinical trial NCT01675284: A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine
Official title: A Phase I, Prospective, Randomized, Open Label, Observer-Blind, Single Center Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Produced in Madin-Darby Canine Kidney (MDCK) Cells
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Bird Flu
Avian Influenza
Influenza A(H5N1)
Keywords: Avian Influenza
Influenza A Virus Subtype H5N1
Inactivated H5N1 Influenza Virion Vaccine
Phase I
Preventive H5N1 vaccination
Lead sponsor: Medigen Biotechnology Corporation
Sponsor class: INDUSTRY
First posted: 2012-08-29
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The focus of this study is to evaluate the safety, reactogenicity and humoral immune responses of the study vaccine when administered at the dose of 7.5 µg HA, 15 µg HA, or 30 µg HA to human subjects.

Detailed description: Since 1997, avian H5N1 influenza in Southeast Asia has caused several human infections and has a high mortality rate. Experts warn that the next influenza pandemic is imminent and could be severe and prevention and control will depend on the rapid production and worldwide distribution of specific pandemic influenza candidate vaccines. An H5N1 influenza vaccine was successfully produced from whole virus grown in MDCK (Madin-Darby canine kidney) cells. These purified inactivated vaccine antigens were safe and could induce immune responses in animal studies. Moreover, when formulated in aluminum phosphate a stronger response was generated even at low doses in animals (Chong et al., 2008; Hu et al., 2008). However, further investigations are necessary before their human safety and immunogenicity can be established. This human phase I clinical study, therefore, evaluates the safety and immunogenicity of adjuvanted H5N1 virion influenza vaccine.

Eligibility criteria: Inclusion Criteria:

* Male or female ≥20 and ≤60 years of age
* In good health as determined by medical history, physical examination, and clinical judgment of the investigator
* Willing and able to comply with all required study visits and follow-up required by this protocol
* Must provide written informed consent

Exclusion Criteria:

* Known or potential exposure to avian influenza virus or any H5N1 HA antigen vaccine
* Had any influenza vaccine within 6 months
* Administered with any vaccine within 30 days
* A history of hypersensitivity to vaccines or inflammatory or degenerative neurological disease
* Receiving chronic administration of immunosuppressants or other immune-modifying drugs within 6 months
* Known HIV, hepatitis B (HBsAg) or hepatitis C seropositivity
* Any medical illness including clinically significant acute pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests
* Receiving immunoglobulins and/or any blood products within the three months
* Acute disease at the time of enrolment
* Psychiatric, addictive, or any disorder, which may compromise the ability to give a truly informed consent for participation of this study or adequate compliance
* Breast feeding or pregnant women

Primary outcomes:
measure: Signs and symptoms solicited by vaccination
timeFrame: A 7-day follow-up period after each vaccine administration
measure: Signs and symptoms unsolicited by vaccination
timeFrame: A 21-day follow-up period after each vaccine administration
measure: Occurrence of adverse events and serious adverse events
timeFrame: Up to 180 days after the first vaccine administration
Secondary outcomes:
measure: Serum antibody titers to H5N1 virus
timeFrame: Day 0
measure: Serum antibody titers to H5N1 virus
timeFrame: Day 21
measure: Serum antibody titers to H5N1 virus
timeFrame: Day 42
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: Pan-Chyr Yang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cheng A, Hsieh SM, Pan SC, Li YH, Hsieh EF, Lee HC, Lin TW, Lai KL, Chen C, Shi-Chung Chang S, Chang SC. The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine - A phase I randomized clinical trial. J Microbiol Immunol Infect. 2019 Oct;52(5):685-692. doi: 10.1016/j.jmii.2019.03.009. Epub 2019 May 18.